Redefining Phenotyping for Clinical Advancements and Variant Prioritization
FDNA’s CEO, Dekel Gelbman, joined two distinguished members of the genetics community—Dr. John Carey (University of Utah) and Dr. Christine Read more
FDNA’s CEO, Dekel Gelbman, joined two distinguished members of the genetics community—Dr. John Carey (University of Utah) and Dr. Christine Read more
The FDNA team is gearing up for ACMG 2020 and we’re excited to share with you new developments and Read more
By Dr. Karen Gripp, Chief Medical Officer at FDNA Next-generation phenotyping (NGP) is characterized by the use of computer learning Read more
2019 was a year of activism, shifts in political ideology, and tech innovation, all resulting in a pause for reflection Read more
The world is bearing witness to a technological revolution that fundamentally changes how we do everything from creating music, Read more
In this case, Face2Gene helped Dr. Cyndy Curry by motivating targeted genetic testing for a family that had long gone Read more
In this case, Face2Gene helped Dr. Lynne Bird focus analysis on a single variant in a setting where the patient Read more
In this case, Face2Gene helped Dr. Li target analysis of a gene which otherwise would not have been analyzed, ultimately Read more
After a successful experience using Face2Gene in his telehealth clinic in Scottsbluff, Dr. Abdul-Rahman decided to start another clinic using Read more
In this case, Face2Gene helped Dr. Omar Abdul-Rahman get patients tested in a more rapid, targeted way, many times before Read more
Rare diseases affect roughly 30 million Americans, yet only 5 percent of the estimated 7,000 known rare diseases have cures Read more
Face2Gene Patient Matching aims to use de-identified facial patterns and other clinical data in your case to find phenotypic similarities Read more
DID YOU KNOW: By adding clinical features to your cases in Face2Gene, you increase the possible syndrome matches to 7,000+. NEW: Include features Read more